Skip to content
OpenCapital
Get started

Annexon ANNX Cash & Equivalents

Cash & Equivalents at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.97B-4.0%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$627.67M+6,105%
Omeros logo
OmerosOMER
$1.91M-55.3%
Vor Biopharma logo
Vor BiopharmaVOR
$169.87M+239%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$75.08M-2.1%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$5.7M-20.0%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's cash & equivalents?
Annexon (ANNX) reported cash & equivalents of $175.21M in Q1 2026.
How has Annexon's cash & equivalents changed year-over-year?
Annexon's cash & equivalents increased by 80.4% year-over-year, from $97.12M to $175.21M.
What is the long-term trend for Annexon's cash & equivalents?
Over 5 years (2020 to 2025), Annexon's cash & equivalents has grown at a -9.6% compound annual growth rate (CAGR), from $268.57M to $162.05M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.